Literature DB >> 20467915

Activation of bombesin receptor subtype-3 influences activity of orexin neurons by both direct and indirect pathways.

Naoki Furutani1, Mari Hondo, Natsuko Tsujino, Takeshi Sakurai.   

Abstract

The neuropeptides orexin A and orexin B (also known as hypocretin 1 and hypocretin 2), produced in lateral hypothalamic neurons, are critical regulators of feeding behavior, the reward system, and sleep/wake states. Orexin-producing neurons (orexin neurons) are regulated by various factors involved in regulation of energy homeostasis and sleep/wakefulness states. Bombesin receptor subtype 3 (BRS3) is an orphan receptor that might be implicated in energy homeostasis and is highly expressed in the hypothalamus. However, the neural pathway by which BRS3 regulates energy homeostasis is largely unknown. We examined whether BRS3 is involved in the regulation of orexin neurons. Using a calcium imaging method, we found that a selective BRS3 agonist [Ac-Phe-Trp-Ala-His-(tauBzl)-Nip-Gly-Arg-NH2] increased the intracellular calcium concentration of orexin neurons. However, intracellular recordings from slice preparations revealed that the BRS3 agonist hyperpolarized orexin neurons. The BRS3 agonist depolarized orexin neuron in the presence of tetrodotoxin. Moreover, in the presence of GABA receptor blockers, picrotoxin and CGP55845, the BRS3 agonist induced depolarization and increased firing frequency. Additionally, double-label in situ hybridization study revealed that Brs3 mRNA was expressed in almost all orexin neurons and many cells around these neurons. These findings suggest that the BRS3 agonist indirectly inhibited orexin neurons through GABAergic input and directly activated orexin neurons. Inhibition of activity of orexin neurons through BRS3 might be an important pathway for regulation of feeding and sleep/wake states. This pathway might serve as a novel target for the treatment of obesity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467915     DOI: 10.1007/s12031-010-9382-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  27 in total

1.  Characterization of the bombesin-like peptide receptor family in primates.

Authors:  Hideki Sano; Scott D Feighner; Donna L Hreniuk; Hisashi Iwaasa; Andreas W Sailer; Jie Pan; Marc L Reitman; Akio Kanatani; Andrew D Howard; Carina P Tan
Journal:  Genomics       Date:  2004-07       Impact factor: 5.736

2.  Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.

Authors:  S A Mantey; H C Weber; E Sainz; M Akeson; R R Ryan; T K Pradhan; R P Searles; E R Spindel; J F Battey; D H Coy; R T Jensen
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

3.  Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.

Authors:  J Hara; C T Beuckmann; T Nambu; J T Willie; R M Chemelli; C M Sinton; F Sugiyama; K Yagami; K Goto; M Yanagisawa; T Sakurai
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

4.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

5.  The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin.

Authors:  C M Edwards; S Abusnana; D Sunter; K G Murphy; M A Ghatei; S R Bloom
Journal:  J Endocrinol       Date:  1999-03       Impact factor: 4.286

6.  Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.

Authors:  R M Chemelli; J T Willie; C M Sinton; J K Elmquist; T Scammell; C Lee; J A Richardson; S C Williams; Y Xiong; Y Kisanuki; T E Fitch; M Nakazato; R E Hammer; C B Saper; M Yanagisawa
Journal:  Cell       Date:  1999-08-20       Impact factor: 41.582

7.  Cloning and expression of the neuromedin B receptor and the third subtype of bombesin receptor genes in the mouse.

Authors:  H Ohki-Hamazaki; E Wada; K Matsui; K Wada
Journal:  Brain Res       Date:  1997-07-11       Impact factor: 3.252

8.  Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity.

Authors:  H Ohki-Hamazaki; K Watase; K Yamamoto; H Ogura; M Yamano; K Yamada; H Maeno; J Imaki; S Kikuyama; E Wada; K Wada
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

9.  The distribution of the orphan bombesin receptor subtype-3 in the rat CNS.

Authors:  C A Jennings; D C Harrison; P R Maycox; B Crook; D Smart; G J Hervieu
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

10.  Hypothalamic orexin neurons regulate arousal according to energy balance in mice.

Authors:  Akihiro Yamanaka; Carsten T Beuckmann; Jon T Willie; Junko Hara; Natsuko Tsujino; Michihiro Mieda; Makoto Tominaga; Ken ichi Yagami; Fumihiro Sugiyama; Katsutoshi Goto; Masashi Yanagisawa; Takeshi Sakurai
Journal:  Neuron       Date:  2003-06-05       Impact factor: 17.173

View more
  3 in total

1.  Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients.

Authors:  Marc L Reitman; Victor Dishy; Allison Moreau; William S Denney; Chengcheng Liu; Walter K Kraft; Alex V Mejia; Mark A Matson; S Aubrey Stoch; John A Wagner; Eseng Lai
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

Review 2.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 3.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.